logo-loader
viewReNeuron Group PLC

Share Purchases by Directors

/**/ h1{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h2{margin:0cm;margin-bottom:.0001pt;font-size:16.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h4{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:16.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h5{margin:0cm;margin-bottom:.0001pt;text-align:justify;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h6{margin:0cm;margin-bottom:.0001pt;text-align:right;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue } visited{ color: purple } .ay{size:595.3pt 841.9pt;margin:72.0pt 106.25pt 72.0pt 90.0pt;}div.ay{}h1.dm{text-indent:117.0pt}span.dn{font-weight:normal}table.dp{margin-left:-5.4pt;border-collapse:collapse}td.dk{width:176.65pt;padding:0cm 5.4pt 0cm 5.4pt}span.dl{font-size:11.0pt;font-family:"Calibri","sans-serif"}td.dh{width:211.6pt;padding:0cm 5.4pt 0cm 5.4pt}h3.di{text-align: right}span.dj{font-size:11.0pt; font-family:"Calibri","sans-serif"} p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;}p.dq{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;margin: 0cm; margin-bottom: .0001pt; text-align: center}span.dr{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}span.ds{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.dt{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: center}p.du{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align:justify}span.db{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}span.dd{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}table.dv{width:423.6pt;margin-left:-5.4pt;border-collapse:collapse;border:none}td.cz{width:72.6pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt} td.cy{width:81.3pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.cx{width:59.55pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.cw{width:81.9pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.cv{width:74.25pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.cu{width:72.6pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.ct{width:81.3pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.cs{width:59.55pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.cr{width:81.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.cq{width:74.25pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}span.co{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black} p.dw{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: justify}table.dx{width:411.1pt}td.ck{padding:0cm 0cm 0cm 0cm}p.dy{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold}span.cm{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black}td.cj{width:25.5%;padding:0cm 0cm 0cm 0cm}span.dz{font-family:"Calibri","sans-serif";color:black;font-size:11.0pt}p.cg{margin-top:0cm;margin-right:0cm;margin-bottom:15.0pt;margin-left: 0cm;text-align:justify;background:white}p.ea{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;margin:0cm;margin-bottom:.0001pt;text-align:justify}p.eb{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext; font-weight: bold; line-height: 115%; margin-bottom: 10.0pt; text-align: center} span.ce{font-size:11.0pt;line-height: 115%;font-family:"Calibri","sans-serif"}table.ec{width:494.45pt;margin-left:-5.4pt;border-collapse:collapse}tr.bx{height:2.3pt}td.bz{width:10.25pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:2.3pt}span.cc{font-size:9.0pt;font-family:"Arial","sans-serif"; color:black}span.cb{font-size:9.0pt;font-family:"Calibri","sans-serif"; color:black}span.ca{font-size:9.0pt;font-family:"Calibri","sans-serif"}td.by{width:462.6pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:2.3pt}tr.bt{height:3.0pt}td.bw{width:10.25pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:3.0pt} td.bv{width:118.1pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:3.0pt}td.bu{width:333.7pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:3.0pt}td.bs{width:10.25pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.bq{width:462.6pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}span.br{font-size: 9.0pt;font-family:"Calibri","sans-serif"}td.bp{width:118.1pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bo{width:333.7pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}span.bn{font-size:9.0pt; font-family:"Calibri","sans-serif"}table.ed{border-collapse:collapse}tr.bk{height:9.25pt} td.bm{width:99.6pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:9.25pt}td.bl{width:99.6pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:9.25pt}tr.bh{height:11.95pt}td.bj{width:99.6pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:11.95pt}td.bi{width:99.6pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:11.95pt}tr.bc{height:20.5pt}td.bf{width:10.25pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:20.5pt}td.be{width:118.1pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:20.5pt}td.bd{width:333.7pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:20.5pt}p.ee{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext; font-weight: bold; line-height: 115%; margin-bottom: 10.0pt} span.ba{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"} /**/
RNS Number : 6843W
ReNeuron Group plc
18 April 2019
 

 

18 April 2019

AIM: RENE

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Share Purchases by Directors

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 18 April 2019 that, on the same day, the following purchases of the Company's ordinary shares of 1p each ("Ordinary Shares") were made by a director of the Company:

 

Name

Title

Number of Ordinary Shares purchased

Total beneficial interest in the Company's Ordinary Shares

Percentage of Company's Total Voting Rights

Professor Sir Chris Evans OBE

Non-executive Director

10,000

254,605

0.802

 

 

ENDS

ENQUIRIES:

 

ReNeuron

+44 (0)20 3819 8400

Olav Hellebø , Chief Executive Officer


Michael Hunt, Chief Financial Officer

 


Buchanan

+44 (0) 20 7466 5000

Mark Court, Sophie Wills, Tilly Abraham

 




Stifel Nicolaus Europe Limited

+44 (0) 20 7710 7600

Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)

 


Nplus1 Singer Advisory LLP

+44 (0) 20 7496 3000

Aubrey Powell, Mark Taylor (Joint Broker)


 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail:

 

Notification and public disclosure of transactions by persons discharging managerial

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Professor Sir Chris Evans OBE

2

Reason for the notification 

a)

Position/status 

Non-Executive Director

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Purchase of ordinary shares

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

2.287

10,000

d)

 

Aggregated information 

N/A

e)

Date of the transaction 

18 April 2019

f)

Place of the transaction 

London Stock Exchange AIM Market

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHGGUBWCUPBGCR

Quick facts: ReNeuron Group PLC

Price: 123.025

Market: LSE
Market Cap: £39.16 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: 'All systems go' for ReNeuron's retinitis pigmentosa...

ReNeuron Group PLC's (LON:RENE) Michael Hunt tells Proactive London's Andrew Scott they've seen a 'rapid and profound' result in the first three patients of the second phase of clinical studies of its human retinal progenitor cells (hRPC). ''What we're seeing is hugely encouraging and I think...

1 week, 1 day ago